FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1847321653> ?p ?o ?g. }

• W1847321653 abstract "Background Fever occurring in a neutropenic patient remains a common life‐threatening complication of cancer chemotherapy. The common practice is to admit the patient to hospital and treat him or her empirically with intravenous broad‐spectrum antibiotics. Oral therapy could be an alternative approach for selected patients. Objectives To compare the efficacy of oral antibiotics versus intravenous (IV) antibiotic therapy in febrile neutropenic cancer patients. Search methods The Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 1) in The Cochrane Library, MEDLINE (1966 to January week 4, 2013), EMBASE (1980 to 2013 week 4) and LILACS (1982 to 2007). We searched several databases for ongoing trials. We checked the conference proceedings of the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) (1995 to 2007), and all references of included studies and major reviews were scanned. Selection criteria Randomised controlled trials (RCTs) comparing oral antibiotic(s) to intravenous antibiotic(s) for the treatment of neutropenic cancer patients with fever. The comparison between the two could be started initially (initial oral) or following an initial course of intravenous antibiotic treatment (sequential). Data collection and analysis Two review authors independently assessed trial eligibility and methodological quality and extracted data. Data concerning mortality, treatment failures and adverse events were extracted from the included studies assuming an 'intention‐to‐treat' basis for the outcome measures whenever possible. Risk ratios (RR) with 95% confidence intervals (CI) were estimated for dichotomous data. Risk of bias assessment was also made in line with methodology of The Cochrane Collaboration. Main results Twenty‐two trials (3142 episodes in 2372 patients) were included in the analyses. The mortality rate was similar when comparing oral to intravenous antibiotic treatment (RR 0.95, 95% CI 0.54 to 1.68, 9 trials, 1392 patients, median mortality 0, range 0% to 8.8%). Treatment failure rates were also similar (RR 0.96, 95% CI 0.86 to 1.06, all trials). No significant heterogeneity was shown for all comparisons but adverse events. The effect was stable in a wide range of patients. Quinolones alone or combined with another antibiotic were used with comparable results. Adverse reactions, mostly gastrointestinal, were more common with oral antibiotics. Authors' conclusions Based on the present data, oral treatment is an acceptable alternative to intravenous antibiotic treatment in febrile neutropenic cancer patients (excluding patients with acute leukaemia) who are haemodynamically stable, without organ failure, and do not have pneumonia, infection of a central line or a severe soft‐tissue infection. The wide CI for mortality allows the present use of oral treatment in groups of patients with an expected low risk for mortality, and further research should be aimed at clarifying the definition of low risk patients." @default.
• W1847321653 created "2016-06-24" @default.
• W1847321653 creator A5015902506 @default.
• W1847321653 creator A5031777825 @default.
• W1847321653 creator A5035946224 @default.
• W1847321653 creator A5049406914 @default.
• W1847321653 creator A5054815696 @default.
• W1847321653 creator A5058378544 @default.
• W1847321653 creator A5073576936 @default.
• W1847321653 date "2013-10-09" @default.
• W1847321653 modified "2023-10-12" @default.
• W1847321653 title "Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients" @default.
• W1847321653 cites W117270364 @default.
• W1847321653 cites W1486006283 @default.
• W1847321653 cites W1512582735 @default.
• W1847321653 cites W1558591958 @default.
• W1847321653 cites W1859854822 @default.
• W1847321653 cites W1883242214 @default.
• W1847321653 cites W1918528668 @default.
• W1847321653 cites W1932756735 @default.
• W1847321653 cites W1963499079 @default.
• W1847321653 cites W1964318600 @default.
• W1847321653 cites W1964618214 @default.
• W1847321653 cites W1966982984 @default.
• W1847321653 cites W1973554864 @default.
• W1847321653 cites W1976058052 @default.
• W1847321653 cites W1977990531 @default.
• W1847321653 cites W1980860286 @default.
• W1847321653 cites W1984494291 @default.
• W1847321653 cites W1991904626 @default.
• W1847321653 cites W1993512217 @default.
• W1847321653 cites W1995941068 @default.
• W1847321653 cites W2004600223 @default.
• W1847321653 cites W2006321866 @default.
• W1847321653 cites W2008049672 @default.
• W1847321653 cites W2011932878 @default.
• W1847321653 cites W2016366382 @default.
• W1847321653 cites W2025147742 @default.
• W1847321653 cites W2025417594 @default.
• W1847321653 cites W2026519975 @default.
• W1847321653 cites W2028766754 @default.
• W1847321653 cites W2029280724 @default.
• W1847321653 cites W2030952865 @default.
• W1847321653 cites W2032861554 @default.
• W1847321653 cites W2036316124 @default.
• W1847321653 cites W2037885820 @default.
• W1847321653 cites W2040000179 @default.
• W1847321653 cites W2041732953 @default.
• W1847321653 cites W2045062203 @default.
• W1847321653 cites W2047893577 @default.
• W1847321653 cites W2050775731 @default.
• W1847321653 cites W2050909687 @default.
• W1847321653 cites W2058142038 @default.
• W1847321653 cites W2058806060 @default.
• W1847321653 cites W2061159110 @default.
• W1847321653 cites W2062125329 @default.
• W1847321653 cites W2062860160 @default.
• W1847321653 cites W2063553737 @default.
• W1847321653 cites W2068817926 @default.
• W1847321653 cites W2069091142 @default.
• W1847321653 cites W2070388124 @default.
• W1847321653 cites W2072842696 @default.
• W1847321653 cites W2073912062 @default.
• W1847321653 cites W2076943885 @default.
• W1847321653 cites W2080352428 @default.
• W1847321653 cites W2082529764 @default.
• W1847321653 cites W2083022489 @default.
• W1847321653 cites W2083792370 @default.
• W1847321653 cites W2084541976 @default.
• W1847321653 cites W2085129263 @default.
• W1847321653 cites W2086916726 @default.
• W1847321653 cites W2088814711 @default.
• W1847321653 cites W2090169076 @default.
• W1847321653 cites W2094119653 @default.
• W1847321653 cites W2096104385 @default.
• W1847321653 cites W2097029485 @default.
• W1847321653 cites W2108906598 @default.
• W1847321653 cites W2112933877 @default.
• W1847321653 cites W2113935918 @default.
• W1847321653 cites W2114424507 @default.
• W1847321653 cites W2120390073 @default.
• W1847321653 cites W2122341933 @default.
• W1847321653 cites W2123825522 @default.
• W1847321653 cites W2128913758 @default.
• W1847321653 cites W2134641172 @default.
• W1847321653 cites W2136975042 @default.
• W1847321653 cites W2145914163 @default.
• W1847321653 cites W2150741204 @default.
• W1847321653 cites W2151156850 @default.
• W1847321653 cites W2157549987 @default.
• W1847321653 cites W2162984346 @default.
• W1847321653 cites W2166858780 @default.
• W1847321653 cites W2168798440 @default.
• W1847321653 cites W2217407321 @default.
• W1847321653 cites W2307031516 @default.
• W1847321653 cites W2318336147 @default.
• W1847321653 cites W2319983332 @default.
• W1847321653 cites W2321647612 @default.
• W1847321653 cites W2321721214 @default.
• W1847321653 cites W2322030277 @default.

• next